Proprietary AI analyst is now available

Vidavo Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vidavo and similar public comparables like Allurion, NRGene, Impedimed, Renalytix and more.

Vidavo Overview

About Vidavo

Vidavo SA develops mobile applications that help citizens on-the-move and medical professionals manage health and wellness. The company serves health and social care providers, policymakers, insurance companies, ICT firms seeking differentiation, patients, telecom operators, and other health-related stakeholders. Its solutions include vida24, vidatrack, and vidahome.


Founded

2005

HQ

Greece

Employees

16

Website

vidavo.eu

Financials (FY)

Revenue: $2M
EBITDA: $947K

EV

$10M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Vidavo Financials

Vidavo reported last fiscal year revenue of $2M and EBITDA of $947K.

In the same fiscal year, Vidavo generated $1M in gross profit, $947K in EBITDA, and $684K in net income.


Vidavo P&L

In the most recent fiscal year, Vidavo reported revenue of $2M and EBITDA of $947K.

Vidavo is profitable as of last fiscal year, with gross margin of 55%, EBITDA margin of 38%, and net margin of 27%.

See analyst estimates for Vidavo
Last FY202320242025202620272028
Revenue$2M$804K$1M$2M
Gross Profit$1M$589K$423K$1M
Gross Margin55%73%33%55%
EBITDA$947K$207K$9K$947K
EBITDA Margin38%26%1%38%
EBIT Margin35%22%(2%)35%
Net Profit$684K$143K($35K)$684K
Net Margin27%18%(3%)27%

Financial data powered by Morningstar, Inc.

Vidavo Stock Performance

Vidavo has current market cap of $10M, and enterprise value of $10M.

Market Cap Evolution


Vidavo's stock price is $9.81.

Vidavo share price increased by 0.1% in the last 30 days, and by 107.6% in the last year.

Vidavo has an EPS (earnings per share) of $0.65.

See more trading valuation data for Vidavo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$10M$10M0.0%0.1%13.0%107.6%$0.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Vidavo Valuation Multiples

Vidavo trades at 3.8x EV/Revenue multiple, and 10.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Vidavo

Vidavo Financial Valuation Multiples

As of June 12, 2026, Vidavo has market cap of $10M and EV of $10M.

Vidavo has a P/E ratio of 15.0x.

Last FY202320242025202620272028
EV/Revenue3.8x11.8x7.5x3.8x
EV/EBITDA10.1x46.0xn/m10.1x
EV/EBIT10.8x53.5xn/m10.8x
EV/Gross Profit6.9x16.2x22.5x6.9x
P/E15.0x71.7xn/m15.0x
EV/FCFn/m57.2xn/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Vidavo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Vidavo Margins & Growth Rates

In the most recent fiscal year, Vidavo reported gross margin of 55%, EBITDA margin of 38%, and net margin of 27%.

See estimated margins and future growth rates for Vidavo

Vidavo Margins

Last FY20242025202720282029
Gross Margin55%33%55%
EBITDA Margin38%1%38%
EBIT Margin35%(2%)35%
Net Margin27%(3%)27%
FCF Margin(1%)(3%)(1%)

Vidavo Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth57%97%
Gross Profit Growth(28%)226%
EBITDA Growth(96%)10800%
EBIT Growth(112%)(4149%)
Net Profit Growth(124%)(2054%)
FCF Growth(119%)(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Vidavo Operational KPIs

Vidavo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Vidavo
Last FY202320242025202620272028
Revenue per Employee$0.2M---
Opex per Employee$0.0M---
G&A Expenses to Revenue3%19%9%3%
R&D Expenses to Revenue14%97%23%14%
Opex to Revenue20%51%35%20%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Allurion----
NRGene1.6x-(5.1x)-
Impedimed1.3x1.1x(1.0x)(1.1x)
Renalytix3.5x3.5x(0.5x)-
Media Lab3.9x-12.5x-
Bullfrog AI62.2x-(1.1x)-
Emimen0.8x0.8x12.1x-
Pheton Holdings----

This data is available for Pro users. Sign up to see all Vidavo competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Vidavo

When was Vidavo founded?Vidavo was founded in 2005.
Where is Vidavo headquartered?Vidavo is headquartered in Greece.
How many employees does Vidavo have?As of today, Vidavo has over 16 employees.
Is Vidavo publicly listed?Yes, Vidavo is a public company listed on Athens Stock Exchange.
What is the stock symbol of Vidavo?Vidavo trades under VIDAVO ticker.
When did Vidavo go public?Vidavo went public in 2010.
Who are competitors of Vidavo?Vidavo main competitors include Allurion, NRGene, Impedimed, Renalytix, Media Lab, Bullfrog AI, Emimen, Pheton Holdings, VSee Health, Synthetic MR.
What is the current market cap of Vidavo?Vidavo's current market cap is $10M.
What is the current revenue of Vidavo?Vidavo's last fiscal year revenue is $2M.
What is the current EV/Revenue multiple of Vidavo?Current revenue multiple of Vidavo is 3.8x.
Is Vidavo profitable?No, Vidavo is not profitable.
How many companies Vidavo has acquired to date?Vidavo hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Vidavo has invested to date?Vidavo hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Vidavo

Lists including Vidavo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial